A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

Adeela Kamal(Forma Therapeutics (United States)), Lia Thao(Forma Therapeutics (United States)), John Sensintaffar(Forma Therapeutics (United States)), Lin Zhang(Forma Therapeutics (United States)), Marcus F. Boehm(Forma Therapeutics (United States)), Lawrence C. Fritz(Forma Therapeutics (United States)), Francis Burrows(Forma Therapeutics (United States))
Nature
September 1, 2003
Cited by 1,391

Abstract


Related Papers